Xenetic Biosciences (XBIO) Investor presentation summary

Strategic transaction and company structure

• Definitive share exchange agreement to combine two companies, creating a global leader in NET-targeted therapeutics.

• Santersus will become a wholly owned subsidiary, with the combined entity trading on Nasdaq under the ticker SNTS.

• Pre-transaction Santersus shareholders expected to own 85% of the combined company, Xenetic stockholders 15%.

• Transaction expected to close in Q4 2026, subject to shareholder approval.

Pipeline and clinical programs

• Four clinical-stage programs target sepsis, SLE, liver transplantation, and large B-cell lymphoma, addressing multi-billion-dollar markets.

• NucleoCapture® is a blood purification device with two FDA Breakthrough Device Designations, targeting rapid EU launch in Q2 2028.

• DNase platform is being studied as an adjunct to CAR T therapy in lymphoma, with initial efficacy data expected Q2 2027.

• Ongoing pivotal multicenter studies for sepsis and SLE, with interim analyses and regulatory submissions planned for 2027-2028.

Clinical results and therapeutic impact

• Over 80 compassionate use cases showed positive outcomes and no adverse events in sepsis, autoimmune disease, and cancer.

• NucleoCapture® demonstrated 100% 7-day survival in sepsis patients, with rapid NET reduction and improved biomarkers.

• SLE patients experienced a 54% reduction in disease activity and significant quality-of-life improvements after three treatments.

• DNase combined with CAR T cells improved survival and tumor clearance in preclinical lymphoma models.